✦ LIBER ✦

Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission

✍ Scribed by Christina S. Chu; Jean Boyer; Daniel S. Schullery; Phyllis A. Gimotty; Victoria Gamerman; James Bender; Bruce L. Levine; George Coukos; Stephen C. Rubin; Mark A. Morgan; Robert H. Vonderheide; Carl H. June

Book ID: 113026885
Publisher: Springer-Verlag
Year: 2011
Tongue: English
Weight: 504 KB
Volume: 61
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s00262-011-1081-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I/II trial of IDD-6, an autologo

A phase I/II trial of IDD-6, an autologous dendritic cell vaccine for women with advanced ovarian cancer in remission

✍ C. Chu; J. Boyer; P. Gimotty; S. Rubin; G. Coukos; M. Morgan; J. Bender; C. June 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Randomized Phase II trial of two high-do

Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study

✍ Patrick J Stiff; Elizabeth J Shpall; P.Y Liu; Sharon P Wilczynski; Natalie S Cal 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 544 KB

A phase I/randomized phase II, non-compa

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

✍ Roger B. Cohen; Corey J. Langer; George Rajan Simon; Peter David Eisenberg; John 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 387 KB

8LBA Biomarker evaluation in the randomi

8LBA Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

✍ B. Johnson; V. Miller; L. Amler; H. Stern; C. Soh; P. O'Connor; F. Kabbinavar 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

P-463 Preliminary results of a multicent

P-463 Preliminary results of a multicenter randomized phase II trial oftwo different combinations of docetaxel (D) and gemcitabine (G) and of cisplatin/gemcitabine (CG) followed by docetaxel as first line therapy for locally advanced or metastatic non small cell lung cancer (NSCLC)

✍ Bernardini, I.; Rinaldi, M.; Crinò, L.; Nardi, M.; De Marinis, F.; Tonato, M.; S 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 130 KB